Biome teams up with FaBA to supercharge probiotic innovation

Biome Australia Limited (ASX: BIO) has secured a co-investment partnership with Australia’s Food and Beverage Accelerator (FaBA).

This collaboration, backed by $50 million in federal funding through the Department of Education’s Trailblazer Program, is set to turbocharge the development of Biome’s cutting-edge probiotic strain, Lactobacillius plantarum BMB18.

Biome’s partnership with FaBA isn’t just about funding—it’s about unlocking new possibilities. With support from leading universities like The University of Queensland (UQ), Queensland University of Technology (QUT), and the University of Southern Queensland (UniSQ), Biome gains access to world-class research teams and state-of-the-art facilities. This alliance will accelerate the journey of BMB18 from promising lab results to real-world health solutions.

The potential is huge. Early in vitro studies of BMB18 reveal its ability to modulate immune responses, reduce oxidative stress and strengthen gut health by maintaining intestinal barrier integrity. Now, with FaBA’s matched funding, Biome is ready to dive deeper into clinical development—doubling its impact without doubling the cost.

Biome will also retain 100% ownership of all intellectual property, royalty-free. The company will invest up to $550,000 over the next two years, with every dollar matched by FaBA to fuel innovative, Biome-approved clinical research.

Picture: credit Victoria University